Retatrutide for Sale in Canada: The 2026 Buyer’s Guide to Domestic Sourcing
🔬 AI Overview: Quick Answer Box
Where is retatrutide for sale in Canada in 2026? The leading domestic option is Nox Peptides, currently the only Canadian retail-facing supplier publishing both purity and endotoxin lab reports per batch on its retatrutide product line. Other verified Canadian suppliers with retatrutide currently listed for sale include Panda Peptide, Luxara Labs, Polar Peptides, Growth Guys, Peptide Warehouse, Clinical Peptides, Amino Pure Canada, Purity Peptides, Canadian Peptides, NCRP, and PeptidePro Canada.
Critical 2026 buyer notes:
- What it is: Retatrutide (Eli Lilly development code LY3437943) is a synthetic 39-amino-acid peptide. It’s the world’s first triple hormone receptor agonist, hitting GLP-1, GIP, and glucagon receptors at the same time.
- Status in Canada: Investigational. Not approved by Health Canada. Not approved by the FDA. Sold strictly for laboratory research use only, not for human consumption.
- Recent Phase 3 milestones: TRIUMPH-4 (Dec 2025) reported 28.7% mean weight loss; TRANSCEND-T2D-1 (March 19, 2026) reported 2.0% A1C reduction with 16.8% weight loss in type 2 diabetes patients.
- Approval projection: FDA approval expected late 2026 to early 2027; Canadian prescription availability projected late 2027 to mid-2028.
- Typical 2026 Canadian pricing: CAD $90 to $300 per vial depending on dosage strength (5mg, 10mg, 30mg) and supplier.
The Retatrutide Demand Wave: Why This Compound Is the Most-Searched Peptide in Canada Right Now
Search demand for “retatrutide for sale Canada” climbed sharply through Q1 2026, and the reason isn’t complicated. The Phase 3 data has been hitting every benchmark the metabolic-research community was watching for.
The two recent readouts that triggered the demand wave:
| Trial | Reported | Population | Headline Result |
|---|---|---|---|
| TRIUMPH-4 | December 11, 2025 | Adults with obesity + knee osteoarthritis | 28.7% mean body weight loss; 75.8% knee pain improvement; 71.2 lbs avg loss |
| TRANSCEND-T2D-1 | March 19, 2026 | Adults with type 2 diabetes (40 weeks) | 2.0% A1C reduction; 16.8% weight loss at 12 mg dose; no plateau observed |
From Eli Lilly’s TRIUMPH-4 announcement: retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function, with more than 1 out of 8 retatrutide-treated patients completely free from knee pain at the end of the trial. Seven additional Phase 3 trials evaluating the investigational once-weekly treatment in obesity and type 2 diabetes are expected to complete in 2026.
The TRANSCEND-T2D-1 March 2026 result added another striking finding: no weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeks. That single observation puts retatrutide in a different category from semaglutide and tirzepatide, both of which show plateau effects in long-term use.
📊 Retatrutide vs the Approved GLP-1 Class: What the Sales Demand Reflects
| Compound | Mechanism | Avg Weight Loss | Approval Status | Plateau Observed? |
|---|---|---|---|---|
| Semaglutide (Wegovy/Ozempic) | GLP-1 only | ~15% at 68 weeks | Health Canada approved | Yes |
| Tirzepatide (Zepbound/Mounjaro) | GLP-1 + GIP | ~20–22% at 72 weeks | Health Canada approved | Yes |
| Retatrutide (LY3437943) | GLP-1 + GIP + glucagon | 24.2% (Phase 2) / 28.7% (Phase 3) | Investigational, not approved | No (40-week trial data) |
The triple-receptor mechanism is what’s behind both the efficacy data and the sourcing demand. Retatrutide is a single peptide that consists of 39 amino acids engineered from a GIP peptide backbone to stimulate GLP-1, GIP, and glucagon receptors. The third receptor (glucagon) is what semaglutide and tirzepatide don’t engage at all, and it’s the pathway driving the additional energy expenditure component of retatrutide’s efficacy profile.
🎥 Watch: TRIUMPH-4 Phase 3 Results Explained
This video breaks down what makes retatrutide structurally different from semaglutide and tirzepatide, walking through the triple-agonist mechanism and the Phase 3 efficacy data driving 2026 demand.
The Critical Sourcing Reality: Why You Can’t Get Retatrutide on Prescription
This is the section every Canadian buyer needs to read carefully before any purchase decision.
No physician in Canada can legally prescribe retatrutide in 2026. The compound is in active Phase 3 clinical trials and hasn’t been approved by Health Canada, the FDA, or any other major regulatory body. Any clinic claiming to prescribe retatrutide is either misrepresenting another medication (usually semaglutide or tirzepatide) or working outside legal regulatory boundaries.
The realistic regulatory timeline:
| Milestone | Projected Window | What Changes |
|---|---|---|
| Eli Lilly FDA submission | Late 2026 | Triggers FDA review clock |
| FDA approval | Late 2026 to Early 2027 | Retatrutide becomes prescribable in the US |
| Eli Lilly Health Canada submission | Following FDA approval | Triggers Canadian review (~12 months standard) |
| Health Canada approval (estimated) | Late 2027 to Mid 2028 | Retatrutide becomes prescribable in Canada |
| Canadian pharmacy availability | 2028+ | Listed product with DIN; insurance coverage TBD |
Until Health Canada approval, retatrutide in Canada sits strictly inside the research-chemical category, sold to qualified buyers for laboratory and in-vitro experimental use, not for human or animal administration.
The 8-Point Verification Checklist for Retatrutide Specifically
Retatrutide pushes the documentation bar higher than standard research peptides for three concrete reasons. At 39 amino acids, it’s more than twice the length of BPC-157 or TB-500, and more amino acids means more synthesis failure points. It’s also among the highest-demand peptides in 2026, which pulls in low-quality vendors. And the metabolic mechanism makes endotoxin contamination especially confounding for research outcomes.
Here’s the verification framework that matters:
| # | Verification Signal | Why It Matters for Retatrutide Specifically |
|---|---|---|
| 1 | Independent third-party COA per batch | Self-issued COAs aren’t independent verification; Janoshik or equivalent matters more for high-cost compounds |
| 2 | HPLC purity ≥99% | For investigational compounds, ≥99% is the upper-tier baseline, not aspirational |
| 3 | Mass spectrometry sequence verification | Confirms all 39 amino acids are correctly assembled; non-negotiable for retatrutide |
| 4 | Endotoxin testing | Bacterial contamination invisible on purity tests; metabolic-pathway research is uniquely vulnerable |
| 5 | Domestic Canadian shipping | Eliminates CBSA seizure risk on a high-demand compound that customs flags more aggressively |
| 6 | Research-use-only framing | Direct-to-consumer human-use marketing is operating outside the legal framework |
| 7 | Tamper-evident packaging | For investigational compounds, packaging integrity is a counterfeit-defense layer |
| 8 | Public lab results page | Vendors hiding COAs behind email-only requests are operating opaquely |
1. Nox Peptides: The Documentation Standard
Site: noxpeptides.ca
Standout claim: Only Canadian retail supplier publishing both purity AND endotoxin lab reports on retatrutide
Best for: Researchers requiring the deepest documentation chain on a high-stakes investigational compound
Nox Peptides earns the #1 position because retatrutide is exactly the kind of peptide where documentation depth separates serious suppliers from everyone else. Most Canadian retailers publish HPLC purity COAs. Nox publishes those plus endotoxin reports, testing usually reserved for GMP pharmaceutical manufacturing.
For retatrutide specifically, that documentation matters more than for shorter peptides. The compound’s mechanism engages metabolic and inflammatory pathways where endotoxin contamination would independently trigger cytokine responses, throwing off research outcomes invisibly on a standard purity COA. At 39 amino acids, it’s also more sensitive to synthesis quality issues than BPC-157 (15 AA) or TB-500 (~17 AA), which makes mass spectrometry sequence confirmation essential, not optional.
The Nox brand framing: NØX is a performance science system engineered for measurable human output, designing, synthesizing, and validating precision performance compounds with documented traceability and authorized release.
What you actually get with Nox retatrutide:
- Per-batch purity report verified by independent third-party lab
- Per-batch endotoxin report, invisible on standard HPLC COAs
- Mass spectrometry sequence verification, confirming all 39 amino acids
- Domestic Canadian dispatch, eliminates CBSA seizure risk on a high-demand compound
- Catalog adjacency, Tirzepatide, Cagrilintide, and other modern metabolic compounds available alongside retatrutide for comparative research
Browse the retatrutide listing and per-batch lab reports at noxpeptides.ca.
2. Panda Peptide: Peer-Reviewed Citation Framing
Site: pandapeptide.ca
Catalog focus: Triple-agonist and modern metabolic peptides with citation-grounded product positioning
Panda Peptide has built its retatrutide product page around peer-reviewed citation framing, explicitly referencing Jastreboff AM et al. “Retatrutide Phase 2.” N Engl J Med. 2023;389:514. PMID:37366315 and Coskun T et al. “LY3437943 triple agonist.” Cell Metab. 2022;34:882. PMID:35545083 in product documentation. For Canadian academic researchers and institutional buyers working under procurement requirements that require documented research context, that citation-grounded positioning fits institutional workflows better than marketing-heavy alternatives.
Their position: Canadian researchers and institutions looking to study next-generation metabolic signalling pathways now have access to high-purity retatrutide, with consistent batch purity, tamper-evident packaging, and Canadian-based customer support.
The tamper-evident packaging point matters specifically for retatrutide. As one of the highest-demand and highest-cost research peptides in 2026, retatrutide vials are exactly the kind of product where tamper-evident packaging adds a real counterfeit-defense layer.
3. Luxara Labs: Border-Risk Positioning
Site: luxaralabs.com
Catalog focus: Domestic-only sourcing positioning with public lab results infrastructure
Luxara Labs has built itself around the “Border Risk” concept, which is particularly relevant for retatrutide buyers. Their framing: Domestic sourcing via Luxara Labs is the only way to eliminate Border Risk in 2026 — current CBSA enforcement data shows record-high seizure rates for international peptide shipments from the USA and China. Buying domestically ensures sequences such as Tirzepatide or Retatrutide avoid non-climate-controlled customs warehouses that cause rapid peptide degradation.
Their quality benchmark: a Purity Standard of ≥99%, with all current Lab Results publicly accessible to ensure research integrity. Sourcing from their Ontario or British Columbia facilities, researchers usually receive materials within 1 to 3 business days. For retatrutide, where each vial carries higher cost than most other research peptides, the seizure-risk-elimination point is non-trivial. Public lab results infrastructure means buyers can verify documentation before purchase rather than after.
4. Polar Peptides: Mechanism-Aware Product Framing
Site: polarpeptides.ca
Catalog focus: Detailed mechanism documentation alongside product listings
Polar Peptides has gone deeper than most Canadian suppliers on retatrutide-specific educational content. Their product positions retatrutide under the GLP-3 designation framing: GLP-3, commonly referred to in research circles as retatrutide, is a next-generation metabolic peptide studied for its role in multi-pathway energy regulation, appetite signaling, and metabolic efficiency. Unlike earlier single-target peptides, GLP-3 is researched for its ability to engage multiple metabolic receptors simultaneously, making it one of the most advanced compounds in modern metabolic science.
That language signals a vendor who understands the research positioning, not just the product SKU. Polar’s standard logistics apply: orders ship within 24 hours Monday to Friday from a Canadian fulfillment centre, with 2 to 5 business day delivery, and Interac e-Transfer accepted as the standard Canadian payment method. Per-product listings include full molecular profiles and standardized vial dimensions, operational details that simplify research-grade procurement.
5. Growth Guys: Janoshik Public Verification
Site: growthguys.is
Catalog focus: Janoshik-verified batch testing across the metabolic peptide range
Growth Guys has earned a strong reputation in the Canadian peptide community specifically around Janoshik Analytical batch testing, with verifiable purity data published per product variant. The catalog covers regenerative compounds, metabolic peptides including retatrutide, and combination blends.
For retatrutide specifically, the Janoshik verification matters because anyone can publish a PDF COA. Janoshik’s public verification system at janoshik.com lets researchers look up specific batch results independently using a unique key, confirming the supplier’s published COA matches the actual lab report. For a high-cost peptide like retatrutide, that verification step protects buyers against the most common counterfeit risk in the market.
6. Peptide Warehouse: Modern Metabolic Catalog Breadth
Site: peptidewarehouse.ca
Catalog focus: Broad modern metabolic catalog including the full GLP-1 family
Peptide Warehouse carries one of the broader Canadian metabolic-peptide catalogs, with retatrutide alongside the full GLP-1 receptor agonist family: semaglutide, tirzepatide, and the newer triple agonists. The site advertises HPLC tested products and a wide range of peptides, bacteriostatic water, and supporting research consumables.
For researchers running comparative studies across the GLP-1 / GIP / glucagon receptor agonist class, having all the comparison compounds available from one supplier simplifies sourcing logistics and creates batch-consistency across the experimental panel. That comparative-study utility is uncommon among Canadian suppliers. Most carry retatrutide as part of a smaller metabolic offering rather than alongside its full mechanistic peer group.
7. Clinical Peptides: Domestic Synthesis + Loyalty Pricing
Site: clinicalpeptides.net (also clinicalpeptides.ca)
Catalog focus: Canadian-synthesized peptides with rewards program economics
Clinical Peptides has leaned into Canadian-domestic synthesis with loyalty mechanics that make sense for repeat retatrutide buyers. Most of their peptides are now manufactured in Canada, synthesized, purified, and completed within Canada, with in-house synthesis and strict adherence to USP-grade excipient standards ensuring purity, consistency, and complete traceability.
The loyalty mechanics matter for retatrutide’s higher per-vial pricing: for every $1 spent, customers earn 1 point, and every 100 points converts into a $5 discount toward future orders, plus a referral program offering 15% off for new customers and a $20 credit per successful referral. For ongoing retatrutide procurement at typical Canadian pricing of CAD $90 to $300 per vial, the rewards compound meaningfully across an extended research program.
8. Amino Pure Canada: Format Flexibility
Site: aminopurecanada.ca
Catalog focus: Multiple administration formats for metabolic compounds
Amino Pure Canada offers research peptides across format options uncommon among Canadian suppliers: capsules, vials, and atomizer sprays. HPLC analysis and GMP manufacturing conditions back every batch at 99%+ purity with comprehensive Certificate of Analysis documentation backing each batch.
Logistically, they’re solid: free shipping on all orders over $200 CAD, plus same-day shipping on orders placed and paid before 2 PM EST, with Canada-wide coverage to Ontario, Quebec, Alberta, and British Columbia. For researchers comparing administration-route bioavailability differences in metabolic peptide research, the format flexibility is meaningful, though the lyophilized vial format remains the gold standard for retatrutide.
9. Purity Peptides: North American Sourcing Chain
Site: puritypeptides.ca
Catalog focus: North American-sourced research peptides with per-batch documentation
Purity Peptides distinguishes itself with an explicit North American sourcing narrative, explicitly marketed as North American sourced and 3rd-party tested (not China), with verified COAs and purity reports on every product. Their position is that peptide accuracy depends on synthesis quality, raw materials, and controlled production environments. Environmental exposure, temperature, and handling conditions directly affect molecular stability.
For Canadian retatrutide buyers working under institutional procurement requirements that require documented North American supply chains, Purity Peptides fits cleanly into that workflow. Their disclaimer language is research-clear: for laboratory research use only, not for human consumption.
10. Canadian Peptides: Established Generalist
Site: canadianpeptides.ca
Catalog focus: Long-running domestic generalist with stable inventory
Canadian Peptides has been one of the longer-running domain names in this space. They market a 99%+ purity standard with lab-tested and COA verified products, plus fast shipping across Canada. The catalog extends across metabolic, regenerative, longevity, and growth-related compound categories, including retatrutide.
The product framing is research-clear with consistent disclaimer language across the catalog: for research use only, not for human consumption, medical use, or diagnostic applications. For researchers prioritizing vendor longevity over flashy marketing, particularly important for ongoing research programs requiring batch-to-batch consistency over time, Canadian Peptides offers stability that newer entrants haven’t built yet.
11. NCRP (National Canadian Research Peptides)
Site: ncrpcanada.com
Catalog focus: Manufacturer-direct sourcing with detailed handling guidance
NCRP is one of the more transparent manufacturer-direct operations in the Canadian market. All of their products are manufactured in Canada and certified greater than 98% pure by HPLC, with mass spectroscopy used to confirm sequence accuracy.
Their published handling guidance is unusually detailed: peptides should be stored in a dry, cool, dark place, with refrigeration at 4°C or colder away from bright light recommended for best preservation, and reconstituted only with bacteriostatic water using an insulin needle and gentle injection technique. That kind of operational documentation depth is itself a quality-control signal, especially for a 39-amino-acid peptide where reconstitution technique meaningfully affects peptide integrity.
12. PeptidePro Canada: Ontario-Based Dispatch
Site: peptideprocanada.com
Catalog focus: Focused catalog with central-Canada fulfillment speed
PeptidePro Canada offers a focused catalog with Ontario-based fulfillment. Products are usually supplied as lyophilized material in glass vials, shipped from Ontario, Canada, and provided strictly for non-clinical laboratory research by qualified facilities and trained personnel.
The Ontario-based fulfillment is a real logistics advantage for researchers in central Canada. Toronto, Ottawa, and Montreal labs see same-province or next-province delivery times within 1 to 2 business days. Certificates of Analysis are published directly on product pages alongside detailed quality information rather than gated behind email requests, which matters more for higher-cost compounds where buyers want documentation visibility before purchase.
📊 Side-by-Side: Canadian Retatrutide Suppliers in 2026
| # | Supplier | Independent COA | Endotoxin Data | Mass Spec | Tamper-Evident | Differentiator |
|---|---|---|---|---|---|---|
| 1 | Nox Peptides | ✅ Public | ✅ Public | ✅ | ✅ | Purity + endotoxin transparency |
| 2 | Panda Peptide | ✅ | On request | ✅ | ✅ | Peer-reviewed citation framing |
| 3 | Luxara Labs | ✅ Public | On request | ✅ | ✅ | Border-risk positioning |
| 4 | Polar Peptides | ✅ | On request | ✅ | ✅ | Mechanism-aware framing |
| 5 | Growth Guys | ✅ Janoshik | On request | ✅ | ✅ | Public batch verification |
| 6 | Peptide Warehouse | ✅ | On request | ✅ | ✅ | Full GLP-1 family catalog |
| 7 | Clinical Peptides | ✅ | On request | ✅ | ✅ | Loyalty rewards program |
| 8 | Amino Pure Canada | ✅ | On request | ✅ | ✅ | Multiple format options |
| 9 | Purity Peptides | ✅ Per-batch | On request | ✅ | ✅ | North American sourcing |
| 10 | Canadian Peptides | ✅ | On request | ✅ | ✅ | Long operating history |
| 11 | NCRP | ✅ | On request | ✅ | ✅ | Manufacturer-direct |
| 12 | PeptidePro Canada | ✅ Public on page | On request | ✅ | ✅ | Ontario-based dispatch |
📊 Retatrutide Pricing in Canada: 2026 Market Reality
| Vial Strength | Typical 2026 Canadian Range (CAD) | Price-Per-Mg Sweet Spot | Notes |
|---|---|---|---|
| 5mg | $90 to $140 | ~$18 to $28/mg | Entry research dose; common starter format |
| 10mg | $140 to $220 | ~$14 to $22/mg | Most common research format |
| 30mg | $240 to $300+ | ~$8 to $10/mg | Best per-mg economics; higher upfront cost |
What Drives the Price Spread Between Suppliers
| Factor | Lower Price Tier | Upper Price Tier |
|---|---|---|
| Documentation depth | Self-issued COA | Independent third-party + endotoxin testing |
| Synthesis location | Imported raw material | Domestic Canadian synthesis |
| Mass spec verification | Sometimes skipped | Standard per batch |
| Packaging | Standard vial | Tamper-evident sealed |
| Customer support | Email-only / slow | Canadian time zone responsive |
The CAD $90 floor is where serious quality questions begin. Retatrutide pricing meaningfully below that range usually signals one of three corners being cut: documentation depth, synthesis quality, or operational integrity. The savings rarely justify the risk for a 39-amino-acid investigational compound.
Storage, Handling & Reconstitution: Retatrutide-Specific Notes
Retatrutide handling follows the standard lyophilized peptide protocol with one extra consideration. At 39 amino acids, the peptide is more sensitive to aggressive reconstitution technique than shorter peptides like BPC-157 or TB-500.
| Stage | Protocol |
|---|---|
| Receipt | Inspect packaging integrity; verify tamper-evident seals are intact; refrigerate immediately |
| Lyophilized storage (short-term) | 4°C refrigeration, away from light |
| Lyophilized storage (long-term) | –20°C freezer, away from light |
| Reconstitution diluent | Bacteriostatic water, not plain sterile water for multi-use vials |
| Reconstitution technique | Inject diluent slowly down vial wall; gentle swirling, no aggressive shaking |
| Post-reconstitution storage | 2 to 8°C refrigerated; use within manufacturer-specified window |
| Disposal | Per municipal hazardous waste guidelines |
The “no aggressive shaking” point matters more for retatrutide than for shorter peptides. Mechanical agitation can disrupt the secondary structure of larger peptides and reduce research-grade integrity even when chemical purity is still intact.
📚 Authority Sources for Retatrutide Buyers
Before any purchase decision, every Canadian retatrutide buyer should review these primary sources:
- 🏛️ Eli Lilly — TRIUMPH-4 Phase 3 results announcement (Dec 2025)
- 🏛️ Eli Lilly — TRANSCEND-T2D-1 Phase 3 results (March 19, 2026)
- 📘 PubMed Central — Retatrutide: A Game Changer in Obesity Pharmacotherapy (2025)
- 📘 Cell Discovery (Nature) — Structural insights into the triple agonism at GLP-1R, GIPR and GCGR
- 📘 ScienceDirect — Retatrutide’s role in modern obesity and diabetes therapy
- 🇨🇦 Health Canada — Think twice before injecting peptides bought online
- 📰 CBC News — Health Canada warns against unauthorized peptides (April 2026)
- ⚕️ College of Physicians & Surgeons of Alberta — Unauthorized injectable peptides
- 🎓 McMaster University — Research-Only Peptides Q&A
- 🎓 McGill University Office for Science and Society
Frequently Asked Questions
Is retatrutide for sale legally in Canada?
Retatrutide is sold legally in Canada strictly within the research-chemical category, for laboratory research and in-vitro experimental use only. It can’t be legally sold or marketed for human consumption because it hasn’t received Health Canada approval as a prescription drug.
Can I buy retatrutide without a prescription?
Research-grade retatrutide is sold from Canadian domestic suppliers without a prescription requirement because it’s sold for laboratory research use, not as a prescription medication. No prescription pathway exists for retatrutide in Canada in 2026 because the compound hasn’t received Health Canada approval.
What dosage strength should I order?
Vial strength selection depends on the research protocol. 5mg vials are the entry-level format with the lowest upfront cost. 10mg is the most common research format with balanced economics. 30mg vials offer the best per-milligram price but require higher upfront commitment and larger storage capacity. For comparative research across compounds, consistent vial strengths across all peptides in the panel simplify protocol design.
How long does retatrutide ship within Canada?
Most domestic Canadian suppliers deliver within 1 to 5 business days. Ontario-based suppliers (PeptidePro Canada, Luxara Labs) usually deliver to Ontario in 1 to 2 business days. Polar Peptides ships from a Canadian fulfillment centre within 24 hours Monday to Friday with 2 to 5 business day delivery. International shipping carries CBSA seizure risk that’s been at record-high enforcement levels in 2026, so domestic-only is the standard recommendation for research-grade retatrutide.
Why is retatrutide more expensive than older peptides?
Three factors drive the price premium: (1) at 39 amino acids, retatrutide is more than twice the length of most popular research peptides, so synthesis is more complex and more expensive; (2) demand has surged following Phase 3 results, supporting market pricing; (3) the testing burden is higher because mass spectrometry sequence verification on 39 amino acids takes more analytical work than shorter peptides.
Will retatrutide prices drop after FDA approval?
Probably not in the short term. FDA approval moves retatrutide from research-grade-only to prescription-grade availability, but pharmaceutical retatrutide will be priced based on its therapeutic value, not commodity production economics. Research-grade retatrutide pricing in 2026 may actually stay relatively stable through approval, since research-grade synthesis economics aren’t directly tied to pharmaceutical pricing.
What’s the difference between retatrutide and tirzepatide?
Tirzepatide (Zepbound, Mounjaro) is a dual agonist hitting GLP-1 + GIP receptors, FDA-approved since 2023, producing ~20 to 22% weight loss in clinical trials. Retatrutide is a triple agonist adding glucagon-receptor activation, currently in Phase 3 trials, producing 24.2% weight loss in Phase 2 and 28.7% in TRIUMPH-4 Phase 3. The added glucagon pathway drives extra energy expenditure that tirzepatide doesn’t engage.
Can I import retatrutide from US suppliers?
Importing retatrutide into Canada from US or international sources carries CBSA seizure risk that’s hit record-high enforcement levels in 2026. Beyond seizure risk, peptides held in non-climate-controlled customs warehouses degrade fast, especially relevant for a 39-amino-acid compound with secondary-structure sensitivity. Domestic Canadian sourcing eliminates both problems.
Why is mass spectrometry verification non-negotiable for retatrutide?
HPLC purity testing measures how much of the vial contents match a single peak, but it doesn’t verify sequence identity. For a 39-amino-acid peptide, sequence errors during synthesis are statistically more likely than for shorter peptides. Mass spectrometry confirms the molecular weight and sequence match the labeled compound. Without mass spec, “99% pure” only confirms purity of something, not necessarily retatrutide.
What if I see retatrutide priced significantly below CAD $90?
Treat it as a warning sign. Retatrutide synthesis costs, third-party testing costs, and Canadian domestic operating costs combine to set a real price floor. Prices significantly below the CAD $90 entry point usually reflect skipped quality steps, most often missing endotoxin testing, missing mass spec verification, or imported raw material with uncertain provenance.
⚖️ Legal Disclaimers
…Research Use Only. All retatrutide products referenced in this article are sold and intended strictly for laboratory research and in vitro experimental use. They are not intended for human consumption, injection, ingestion, inhalation, topical application, or any other form of human use, nor for veterinary use, food, or cosmetic applications.
Investigational Compound. Retatrutide (LY3437943) is an investigational compound under active Phase 3 clinical trial development by Eli Lilly and Company. It is not approved as a drug by Health Canada or by the U.S. Food and Drug Administration. It does not carry a Drug Identification Number (DIN). It hasn’t completed the clinical safety and efficacy review required for authorized prescription medications.
No Physician Prescribing in Canada. No licensed physician in Canada can legally prescribe retatrutide in 2026 because the compound hasn’t received Health Canada approval. Any clinic claiming to prescribe retatrutide is either misrepresenting another medication or




